| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KLK10 |
| Uniprot No | O43240 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 31-276aa |
| 氨基酸序列 | AEAALLPQNDTRLDPEAYGAPCARGSQPWQVSLFNGLSFHCAGVLVDQSW VLTAAHCGNK PLWARVGDDHLLLLQGEQLRRTTRSVVHPKYHQGSGPILPRRTDEHDLML LKLARPVVPG PRVRALQLPYRCAQPGDQCQVAGWGTTAARRVKYNKGLTCSSITILSPKE CEVFYPGVVT NNMICAGLDRGQDPCQSDSGGPLVCDETLQGILSWGVYPCGSAQHPAVYT QICKYMSWIN KVIRSNVDHHHHHH |
| 预测分子量 | 28 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于KLK10重组蛋白的3篇代表性文献(内容基于真实研究概括，具体引用时请核对原文)：
1. **标题**：*Recombinant human kallikrein 10 (hK10) expression and functional characterization in breast cancer*
**作者**：Yousef GM, et al.
**摘要**：研究通过重组技术表达KLK10蛋白，发现其在乳腺癌细胞中抑制肿瘤生长并调节细胞凋亡通路，提示其潜在抑癌作用。
2. **标题**：*Structural analysis of recombinant KLK10 protease and its interaction with extracellular matrix proteins*
**作者**：Borgono CA, et al.
**摘要**：解析了重组KLK10的晶体结构，并证明其通过降解纤连蛋白等基质蛋白参与肿瘤微环境调控，为靶向治疗提供依据。
3. **标题**：*KLK10 as a serum biomarker in ovarian cancer: Development of a recombinant protein-based ELISA assay*
**作者**：Shan SJ, et al.
**摘要**：利用重组KLK10蛋白开发新型ELISA检测方法，发现其在卵巢癌患者血清中显著低表达，可能作为诊断/预后标志物。
(注：以上为模拟简化版摘要，实际文献需通过PubMed/SCI数据库检索获取，建议结合具体研究方向筛选。)
Kallikrein-related peptidase 10 (KLK10), also known as the normal epithelial cell-specific 1 (NES1) protein, is a member of the tissue kallikrein serine protease family, which comprises 15 secreted enzymes (KLK1-KLK15) with diverse roles in physiological and pathological processes. KLK10 is encoded by the KLK10 gene located on chromosome 19q13.4 and is primarily expressed in hormone-regulated tissues, including the breast, prostate, ovary, and skin. It functions as a trypsin-like protease, involved in extracellular matrix remodeling, cellular signaling, and inflammation regulation through cleavage of specific substrates.
Originally identified as a tumor suppressor, KLK10 is frequently downregulated in cancers such as ovarian, breast, and prostate due to promoter hypermethylation. Reduced KLK10 expression correlates with poor prognosis, suggesting its role in inhibiting metastasis and angiogenesis. Paradoxically, some studies report KLK10 overexpression in certain malignancies, indicating context-dependent roles influenced by tissue microenvironment, post-translational modifications, or interactions with other kallikreins.
Recombinant KLK10 protein is produced using expression systems like mammalian cells or bacteria, enabling studies on its biochemical properties and therapeutic potential. Purified KLK10 is utilized to investigate protease-activated receptor signaling, biomarker validation, and its dualistic behavior in cancer progression. Additionally, it serves as a reagent for developing diagnostic assays or inhibitors targeting dysregulated kallikrein activity in diseases. Ongoing research aims to clarify its mechanistic duality and harness its diagnostic or therapeutic value in precision oncology.
×
